iShares Genomics Immunology and Healthcare ETF
IDNA
63 hedge funds and large institutions have $65.5M invested in iShares Genomics Immunology and Healthcare ETF in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 20 increasing their positions, 12 reducing their positions, and 4 closing their positions.
400% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 4
67% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 12
50% more capital invested
Capital invested by funds: $43.7M → $65.5M (+$21.8M)
31% more funds holding
Funds holding: 48 → 63 (+15)
0.04% less ownership
Funds ownership: 19.62% → 19.58% (-0.04%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$4.29M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$2.2M |
| 3 |
LPL Financial
San Diego,
California
|
+$1.92M |
| 4 |
Jane Street
New York
|
+$1.46M |
| 5 |
WAP
Wealthcare Advisory Partners
West Chester,
Pennsylvania
|
+$1.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$934K |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$677K |
| 3 |
JWCA
J.W. Cole Advisors
Tampa,
Florida
|
-$265K |
| 4 |
RCS
Retirement Capital Strategies
San Jose,
California
|
-$63.5K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$39.1K |
IDNA Hedge Fund Activity: Q4 2020 in Review
63 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in iShares Genomics Immunology and Healthcare ETF (IDNA) for Q4 2020, worth a combined $65.5M — up 50% from $43.7M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new IDNA positions and 4 closed out — a net gain of 16 holders — while 20 added to existing stakes and 12 trimmed.
The largest buyer was UBS Group, adding an estimated $4.29M. The largest seller was Citadel Advisors, exiting entirely with an estimated $934K sold.
- 63 institutional investors held iShares Genomics Immunology and Healthcare ETF (IDNA) as of Q4 2020, up from 48 in Q3 2020.
- Funds reported $65.5M of iShares Genomics Immunology and Healthcare ETF stock for Q4 2020, up 50% quarter-over-quarter.
- 20 funds opened new iShares Genomics Immunology and Healthcare ETF positions in Q4 2020 and 4 closed out, a net change of +16 holders.
- The largest iShares Genomics Immunology and Healthcare ETF buyer in Q4 2020 was UBS Group, an estimated $4.29M added.
- The largest iShares Genomics Immunology and Healthcare ETF seller in Q4 2020 was Citadel Advisors, an estimated $934K sold.
Based on aggregated 13F filings for Q4 2020.